Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
135
resultados
Última actualización
23/08/2025 [07:07:00]
Resultados 25 a 50 de 135
Resumen de: AU2025205555A1
Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject. Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject. ul u l i s c l o s e d h e r e i n a r e n u c l e i c a c i d m o l e c u l e s e n c o d i n g a e v e r e c u t e e s p i r a t o r y y n d r o m e c o r o n a v i r u s ( - o - ) s p i k e a n t i g e n , - o - s p i k e a n t i g e n s , i m m u n o g e n i c c o m p o s i t i o n s , a n d v a c c i n e s a n d t h e i r u s e i n i n d u c i n g i m m u n e r e s p o n s e s a n d p r o t e c t i n g a g a i n s t o r t r e a t i n g a - o - i n f e c t i o n i n a s u b j e c t
Resumen de: WO2025162130A1
The present invention relates to the field of pharmacological research, and specifically relates to a compound as shown in general formula (I), or a pharmaceutically acceptable salt, tautomer, enantiomer, diastereomer, racemate, hydrate, ester, solvate, metabolic precursor or prodrug thereof, a preparation method therefor, a pharmaceutical combination comprising same, and a use of the compound in the prevention and/or treatment of respiratory diseases caused by viruses (such as SARS-CoV2, SARS-CoV, and MERS-CoV) and in the inhibition of nonstructural proteins of the related viruses, such as a papain-like protease protein.
Resumen de: WO2025166067A1
Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of SARS-CoV-2; and (ii) a complement binding polypeptide. The disclosure also provides polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.
Resumen de: WO2025163362A1
The proposed invention, which combines cellulose acetate nanofibers with hyssop essential oil, offers a unique approach by integrating both advanced filtration technology and natural antiviral agents. This dual functionality sets it apart from existing patents, potentially providing enhanced protection against airborne pathogens while maintaining breathability and comfort.
Resumen de: WO2025164815A1
The present invention relates to a novel peptide having binding affinity to ACE2 and uses thereof and, more specifically, to: a peptide represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4, and having binding affinity to ACE2; a nanocarrier and a drug complex, each comprising the peptide; and a pharmaceutical composition for preventing or treating COVID-19, comprising the peptide, the nanocarrier, or the drug complex. The novel peptide according to the present invention can be used to increase the COVID-19 therapeutic effect through specific binding to ACE2-expressing cells.
Resumen de: AU2023411024A1
Disclosed herein are compositions comprising a Siglec-9 inhibitor, a fragment thereof, a variant thereof, or a combination thereof, and methods of use thereof for enhancing an immune response. Also disclosed herein is a therapeutic composition comprising a combination of Siglec-9 inhibitor and an anti-SARS-CoV-2 antibody, or a bispecific anti- Siglec-9/anti-SARS-CoV-2 antibodies and methods of use for treating or preventing COVID- 19.
Resumen de: US2025249089A1
Recombinant plasmids and immunogenic DNA compositions including a recombinant plasmid which carries the gene sequence encoding the Spike protein or the gene sequence encoding the NP protein, with the capacity to prevent high viral loads and moderate and severe clinical forms of the disease by stimulating the immune system, both against the ancestral strain of SARS-CoV-2 and influenza strains against different variants of concern that are currently circulating are disclosed. A bivalent recombinant plasmid and a immunogenic composition including the bivalent recombinant plasmid which carries the gene sequence encoding the NP and Spike protein, with the capacity to prevent high viral loads and moderate and severe clinical forms of the disease by stimulating the immune system, both against the influenza strain and SARS-COV-2 strain against different variants of concern that are currently circulating are disclosed.
Resumen de: AU2024225919A1
The present disclosure provides multi ci str onic vaccines and method for producing and using the same in preventing infection or transmission, or reducing severity of disease caused by influenza and/or SARS-Cov-2 virus in a subject. Multicistronic vaccines of the disclosure can be administered via intramuscular, intranasal, or inhalation route. In one particular embodiments, the disclosure provides a recombinant adenovirus comprising at least two different extraneous oligonucleotides that are capable of stimulating an immune response in a subject. Each of the oligonucleotide independently comprises an oligonucleotide that encodes either influenza or SARS-Cov-2 virus antigens.
Resumen de: CN120051481A
The invention discloses a phage for specifically capturing SARS-CoV-2 virus, the phage is an engineered M13 phage, so that an FGKGGYEKTWKLGD sequence peptide or an EFTSKAR sequence peptide is displayed on a P8 protein of a shell of the phage, and the peptide has specific affinity to a spike S1 protein of the SARS-CoV-2 virus.
Resumen de: WO2024068265A2
The present invention relates to the use of vaccines comprising virus-like particles displaying at least one SARS-CoV-2 antigen, such as the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, as vaccine boosters. Antigens are displayed on virus-like particles (VLPs) and produce an immune response in vaccinated subjects. The invention also relates to methods of treatment using the recombinant VLPs as boosters to treat and/or prevent infection with SARS-CoV-2, and methods of preparation thereof.
Resumen de: WO2024068777A1
The present invention relates to therapeutic proteins and medical uses thereof. The present invention relates to modified ACE2 protein having increased binding affinity for the SARS- CoV-2 spike protein compared to wildtype ACE2 protein, wherein said modified ACE2 protein is lacking enzymatic activity and is fused to (i) a modified Fc domain of human immunoglobulin, wherein the Fc domain has either enhanced immunostimulating activity (Fc+) or attenuated immunostimulating activity (Fc-) or (ii) a protein that specifically binds to T cells or further enhances immunostimulating activity. The invention also relates to a polynucleotide encoding the modified ACE2 protein of the present invention, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide or the vector or expression construct, and a non-human transgenic organism comprising the polynucleotide or the vector or expression construct. Moreover, the present invention relates also to a method for the manufacture of a modified ACE protein according to the present invention and to a medicament comprising the modified ACE2 protein, the polynucleotide or the vector or expression construct of the invention. Furthermore, the invention relates to medical uses of the modified ACE2 protein, the polynucleotide or the vector or expression construct in treating and/or preventing a disease or disorder associated with SARS-CoV-2 infection. Finally, the invention provides a kit comprising th
Resumen de: LU508111B1
The invention belongs to the field of biotechnology, and specifically discloses a method for analyzing an influence of COVID-19 on a tuberculosis patient and a possible drug based on system biology and bioinformatics, which comprises the following steps of: 10 (1) carrying out differential expressed gene analysis on two PBMC data sets of COVID-19 and tuberculosis to obtain two sets of differential expressed genes, and intersecting the two sets of differential expressed genes to obtain common differential expressed genes; (2) constructing a protein-protein interaction network, which is a PPI network, according to the common differential expressed genes in the step (1); and analyzing and selecting hub 15 genes for the PPI network; and (3) carrying out drug prediction according to the hub genes determined in the step (2) by using an enrichr platform, and selecting a drug capable of treating COVID-19 and tuberculosis at the same time.
Resumen de: MX2025005412A
The present disclosure relates to a fusion protein comprising an ectodomain of a viral fusion protein linked to one or more heptad repeat(s) (HR(s)) from a SARS-COV-2 spike (S) protein or a respiratory syncytial virus (RSV) F protein, and the uses thereof. The viral fusion proteins are suitable for use as vaccines.
Resumen de: MX2025002237A
A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.
Resumen de: MX2025007248A
An application of shenling baizhu in the preparation of a drug for treating psychoneurological symptoms of recovered COVID-19 patients.
Resumen de: US2025242059A1
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Resumen de: US2025241978A1
A peptide for prevention and treatment of COVID-19 in a patient, wherein the peptide consists of 7-17 amino acids and includes the hexamer TX1EX2X3E, wherein X1, X2 and X3 can be any natural or non-natural amino acid, and wherein the peptide does not exhibit TNF-receptor-binding activity. Suitable peptides include solnatide (cyclo-CGQRETPEGAEAKPWYC).
Resumen de: US2025242013A1
The disclosure provides an animal cell stably expressing a virus-like particle (VLP). The disclosure also provides a method for manufacturing a virus-like particle, a virus-like particle, a vaccine composition, a method for preventing viral infection, and a method for producing antibodies.
Resumen de: AU2023412582A1
Provided is use of Shenling Baizhu in preparing a medicament for treating post-healing sequelae of a novel coronavirus infected person. The sequela is selected from at least one of short of breath, fatigue and weakness, inappetence, and diarrhea. The Shenling Baizhu is prepared from the following raw materials in parts by weight: 400 parts of ginseng, 400 parts of poria cocos, 400 parts of Rhizoma Atractylodis macrocephalae stir-fried with bran, 400 parts of Chinese yam, 300 parts of fried white hyacinth beans, 200 parts of lotus seeds, 200 parts of coix seeds stir-fried with bran, 200 parts of Fructus amomi, 200 parts of Platycodon grandiflorum, and 400 parts of liquorice.
Resumen de: AU2024251861A1
The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, the composition including lactic acid bacteria. The chemosensory disorder may be a chemosensory disorder that occurs after SARS-CoV-2 virus infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect for a chemosensory disorder, and in that pharmaceuticals or foodstuffs that are safe for mammals, including humans, can be provided.
Resumen de: US2025243282A1
Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.
Resumen de: US2025244326A1
A method of diagnosing long-COVID in a subject, the method comprising: (a) measuring the level of one or more biomarkers in a test sample obtained from the subject, and (b) comparing the level of the one or more biomarkers in the test sample with a healthy control and/or an acute COVID-19 reference level value of said one or more biomarkers, wherein an increase in the level of the one or more biomarkers in the test sample relative to the healthy control and/or acute COVID-19 reference level value of said one or more biomarkers is indicative of long-COVID diagnosis, and wherein the one or more biomarkers are selected from Table 5. In one embodiment, the one or more biomarkers include ANG-1, P-Sel and MMP-1. A method of treating long-COVID comprising administering to a subject one or more of the biomarkers are selected from Table 5.
Resumen de: US2025244325A1
The present disclosure relates to anti-SARS-COV-2 antibodies and uses thereof in detecting intact multimeric and/or intact trimeric severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike protein in a sample.
Resumen de: US2025243172A1
NLRP3 selective inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, acute myocardial infarction, heart failure, arthritis, diabetes, gout, COVID-19, and autoinflammatory diseases.
Nº publicación: US2025244338A1 31/07/2025
Solicitante:
AION HEALTHSPAN INC [US]
UNIV OF MIAMI [US]
AION HEALTHSPAN, INC,
University of Miami
Resumen de: US2025244338A1
The present disclosure relates to methods of testing immunomodulatory activity of cells, including, for example, mesenchymal stem cells and uses of said cells that are determined as having immunomodulatory activity for treating COVID-19 related acute respiratory distress syndrome (ARDS). Disclosed herein are in vitro methods of evaluating mesenchymal stem cells for their effective immunomodulatory effects in vivo.
BOPI
Sede Electrónica
